Loading patent…
OwnerSherif Daouti, Chanrika Kumar +1inventors
InventorsSherif Daouti, Chanrika Kumar, Brian Latario
Estimating the term…
The invention discloses PI3K, PKB, IL-1, and OSM as suitable targets for the development of new therapeutics to treat, prevent or ameliorate osteoarthritis (OA). The invention relates to methods to treat, prevent or ameliorate OA and pharmaceutical compositions therefor comprising substances with inhibitory effects on PI3K and/or PKB enzyme activity and/or gene expression and IL-1 and/or OSM activity or gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat OA, comprising identifying compounds that can effect PI3K and/or PKB activity and/or gene expression and/or IL-1 or OSM activation of PI3K and/or PKB activity and/or gene expression which leads to downregulation of AGG-1 and/or COL-3 and thus prevent, treat or ameliorate OA in vivo.
A method to prevent, treat, or ameliorate a disease associated with or caused by altered levels of Aggrecanase-1 or Collagenase-3 comprising administering to a subject in need thereof an effective amount of a compound capable of modulating Phospho-Inositide 3 Kinase, Protein Kinase B, IL-1, or OSM and through said modulation alter gene and/or protein expression of Aggrecanase-1 or Collagenase-3.
A method to prevent, treat, or ameliorate osteoarthritis comprising administering to a subject in need thereof an effective amount of a compound capable of modulating Phospho-Inositide 3 Kinase, Protein Kinase B, IL-1, or OSM, and through said modulation alter gene and/or protein expression of Aggrecanase-1 or Collagenase-3.
A method to prevent, treat, or ameliorate osteoarthritis comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a modulator of Phospho-Inositide 3 Kinase, Protein Kinase B, IL-1, OSM and through said modulation alter gene and/or protein expression of Aggrecanase-1 or Collagenase-3.
A method to identify modulators useful to prevent, treat, or ameliorate osteoarthritis comprising assaying for the ability of a candidate modulator to inhibit Phospho-Inositide 3 Kinase, Protein Kinase B, IL1, or OSM, and through said inhibition alter gene and/or protein expression of Aggrecanase-1 or Collagenase-3.
A pharmaceutical composition comprising a Phospho-Inositide 3 Kinase modulator, Protein Kinase B modulator, IL-1 modulator, or OSM modulator in an amount effective to prevent, treat, or ameliorate osteoarthritis in a subject in need thereof.
A method to diagnose subjects affected with active or nascent osteoarthritis who may be suitable candidates for treatment with Phospho-Inositide 3 Kinase, Protein Kinase B modulators, IL-1 modulators, or OSM modulators comprising assaying mRNA levels of a substance selected from one or more of the following:
A method to prevent, treat, or ameliorate osteoarthritis comprising:
A method to diagnose subjects affected with active or nascent osteoarthritis who may be suitable candidates for treatment with Phospho-Inositide 3 Kinase modulators, Protein Kinase B modulators, IL-1 modulators, or OSM modulators comprising assaying mRNA levels of a substance selected from one or more of the following:
A method to prevent, treat, or ameliorate osteoarthritis comprising:
A diagnostic kit for detecting mRNA levels and/or protein levels of a substance selected from one or more of the following:
Use of a compound capable of modulating Phospho-Inositide 3 Kinase Protein Kinase B, IL-1, or OSM for the manufacture of a medicament for the treatment of a disease associated with or caused by altered levels of Aggrecanase-1 or Collagenase-3.
Use of a compound capable of modulating Phospho-Inositide 3 Kinase Protein Kinase B, IL-1, or OSM for the manufacture of a medicament for the treatment osteoarthritis.
Use of 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) for the manufacture of a medicament for the treatment of a disease associated with or caused by altered levels of Aggrecanase-1 or Collagenase-3.
Use of 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) for the manufacture of a medicament for the treatment of osteoarthritis.
Dependencies are inferred from the claim text.